 Mephenytoin
"Mephenytoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.
| Descriptor ID |
D008617
|
| MeSH Number(s) |
D03.383.129.308.432.555.620
|
| Concept/Terms |
Mephenytoin- Mephenytoin
- Methyl Phenetoin
- Phenetoin, Methyl
- Methoin
- 5-Ethyl-3-Methyl-5-Phenylhydantoin
- 5 Ethyl 3 Methyl 5 Phenylhydantoin
- Mefenetoin
|
Below are MeSH descriptors whose meaning is more general than "Mephenytoin".
Below are MeSH descriptors whose meaning is more specific than "Mephenytoin".
This graph shows the total number of publications written about "Mephenytoin" by people in this website by year, and whether "Mephenytoin" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text, click here.
Below are the most recent publications written about "Mephenytoin" by people in Profiles.
-
Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999 Aug; 290(2):635-40.
-
Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 1998 Jan; 284(1):356-61.
-
Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997 Feb; 7(1):59-64.
-
Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics. 1996 Aug; 6(4):329-39.
-
Br?sen K, de Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogenetics. 1995 Oct; 5(5):312-7.
-
de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995 Oct; 58(4):404-11.
|
Similar Concepts
![expand description]()
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|